drugset / Trial / NCT04655092
Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 3 open-label, multicenter, single arm study designed to evaluate the efficacy and safety and tolerability of P1101 patient with PV or ET in long-term.
Timeline
- Start
- 2021-01-19
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ropeginterferon alfa-2b | Protein / enzyme biologic | 250 ug | Subcutaneous |
| Subject | Ropeginterferon alfa-2b | Protein / enzyme biologic | 500 ug | Subcutaneous |